SCHEMBL7127288

SCHEMBL7127288

CC(=O)CC(=O)OC1=CC=CCC1=S

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.35
GAA P10253 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5676961 0.85
SCHEMBL6942777 0.83 ESR1 (0.35)
SCHEMBL6278260 0.81 LMNA (0.31) GAA
SCHEMBL11002171 0.80 LMNA (0.40)
SCHEMBL1756465 0.78 ALOX15 (0.31)
SCHEMBL1756477 0.78 ALOX15 (0.31)
SCHEMBL18203168 0.78
SCHEMBL19332068 0.76 KMT2A (0.36) GAA
SCHEMBL8958271 0.76 MEN1 (0.31)
SCHEMBL5499066 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0912467-B1 ASYMMETRIC HYDROGENATION METHOD OF A KETONIC COMPOUND AND DERIVATIVE RHODIA CHIMIE SA (FR) 2002-04-24 EP claimed
US-20030225297-A1 Process for preparing chiral diphosphines RHODIA CHIMIE 2003-12-04 US disclosed
US-6646106-B1 Polymerizing chiral diphosphine having a C2 axis of symmetry, with one or several polymerizable monomers, said chiral diphosphine consisting of a chiral body bearing two identical functional groups RHODIA CHIMIE (FR) 2003-11-11 US disclosed
US-6610875-B1 Forming bidentate ligands ofr assymetric catalysts; bromina-ting diaryldiol; esterifying with sulfonic acid; substituting cyano for bromine groups; coupling with a dicyclophosphine RHODIA CHIMIE (FR) 2003-08-26 US disclosed
US-6166257-A METAL COMPLEX OF AN OPTICALLY ACTIVE BIS(1-PHOSPHA-2,3-DIPHENYL-4,5-DIMETHYLNORBORNADIENE) RHODIA CHIMIE (FR) 2000-12-26 US disclosed
EP-0295109-B2 Process for preparing optically active alcohol TAKASAGO PERFUMERY CO LTD (JP) 1996-09-04 EP disclosed
EP-0367508-B1 MERCAPTOALKYL ACETOACETATES, USE THEREOF AND A PROCESS FOR THE PREPARATION OF MERCAPTOALKYL ACETOACETATES ROHM AND HAAS COMPANY (US) 1992-07-22 EP disclosed
US-4960924-A Mercaptoalkyl acetoacetates ROHM AND HAAS COMPANY (US) 1990-10-02 US disclosed
EP-0367508-A1 Mercaptoalkyl acetoacetates, use thereof and a process for the preparation of mercaptoalkyl acetoacetates ROHM AND HAAS COMPANY (US) 1990-05-09 EP disclosed
EP-0295109-A1 Process for preparing optically active alcohol Takasago International Corporation (JP) 1988-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225297-A1 Process for preparing chiral diphosphines CYP1A1, NR5A1, AR MGAM 4708/4885GAA 3491/4885SI 4612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.